Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Sells $23,580.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni sold 3,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $23,580.00. Following the completion of the transaction, the senior vice president now owns 16,341 shares in the company, valued at $128,440.26. The trade was a 15.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $8.07 on Friday. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The stock has a market cap of $430.78 million, a price-to-earnings ratio of -4.10 and a beta of 2.00. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business’s fifty day moving average is $8.22 and its 200 day moving average is $8.06.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ZVRA. International Assets Investment Management LLC grew its holdings in Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $92,000. XTX Topco Ltd bought a new position in Zevra Therapeutics during the 3rd quarter valued at approximately $94,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Zevra Therapeutics during the fourth quarter valued at $94,000. 35.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Finally, Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.57.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.